Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Non-Inferiority Trial Design With Historical Comparison To Be Clarified By FDA

Executive Summary

FDA is working on clarifying issues related to how to structure non-inferiority trials when historical comparisons are necessary.

You may also be interested in...



International Harmonization Should Focus On Post-Marketing Activities - HRG

International harmonization efforts should include an emphasis on post-marketing activities, Public Citizen's Health Research Group Deputy Director Peter Lurie, MD, said at an FDA public meeting May 16 on the future of the International Conference on Harmonization.

International Harmonization Should Focus On Post-Marketing Activities - HRG

International harmonization efforts should include an emphasis on post-marketing activities, Public Citizen's Health Research Group Deputy Director Peter Lurie, MD, said at an FDA public meeting May 16 on the future of the International Conference on Harmonization.

Refludan Coronary Syndrome Use Not Supported By Heparin-Placebo Data

Aventis was unable to convince FDA and its Cardiovascular & Renal Drugs Advisory Committee that its thrombin inhibitor Refludan is superior to placebo in the treatment of acute coronary syndromes by inference from historical data comparing heparin and placebo.

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel